Neurology

Phase 3 data show that ocrelizumab (Ocrevus) may delay the progression of disability, such as the need for a wheelchair, in patients with primary progressive multiple sclerosis (PPMS).

Researchers investigated whether high body mass index is a risk factor not only for a greater risk of multiple sclerosis, but also for advancing to the secondary progressive stage of the disease.

Top news of the day from across the health care landscape

Researchers identified a primary mechanism of inflammatory demyelination in the central nervous system during multiple sclerosis, which may lead to new therapeutic approaches.

Researchers aimed to assess the relationship between fatigue in multiple sclerosis and inflammatory or other immunomediated markers.

A retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS)

Ocrelizumab showed a sustained reduction in underlying disease activity and improved cognitive function in patients with relapsing multiple sclerosis.

Indazole chloride may be able to reduce disability burden in patients with multiple sclerosis by producing good inflammation that promotes axon myelination.

The results of a recent study provide important insights into what might influence the development of multiple sclerosis.

Officials with the FDA have approved fingolimod (Gilenya, Novartis) for the treatment of relapsing multiple sclerosis (MS) in pediatric patients aged 10 years and older.

Officials with the FDA have approved fingolimod (Gilenya, Novartis) for the treatment of relapsing multiple sclerosis in pediatric patients aged 10 years and older, making it the first FDA-approved drug to treat MS in this population.

Fingolimod (Gilenya, Novartis) is the first FDA-approved treatment to treat multiple sclerosis in pediatric patients.

Patients with relapsing MS who switched from interferon therapy to teriflunomide (Aubagio) experienced improvements in treatment satisfaction.

Study finds improving adherence to disease-modifying multiple sclerosis medications could reduce clinical relapses while saving on medical costs.

New analysis from a phase 3 trial reports that oral, once-daily siponimod (BAF312) consistently reduced disability progression in patients with secondary progressive multiple sclerosis.

The results of a recent study have indicated that teenagers who experience a concussion face an elevated risk of developing multiple sclerosis (MS) later in life.

Top news of the week from Specialty Pharmacy Times.

Treating mental health disorders may reduce the risk of progressive multiple sclerosis.

Treatment with siponimod reduced brain volume loss by 23% in patients with secondary progressive multiple sclerosis.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

Individuals who experience high sun exposure during childhood or young adulthood may be less likely to develop multiple sclerosis.

A continuing concern is HIV-associated neurologic syndromes.

Case studies with an OTC focus.

Idebenone was not found to delay disease progression in multiple sclerosis compared with placebo.

Induced neural stem cells may hold the key to reducing multiple sclerosis-related central nervous system damage.

Evobrutinib is an oral inhibitor of Bruton’s tyrosine kinase in development for several autoimmune diseases.

Patients with multiple sclerosis may be at a higher risk of developing mental health conditions.

Biogen and AbbVie recently announced a voluntary, worldwide withdrawal of daclizumab (Zinbryta®).